Practical comparison guide

Choosing A Center

A careful comparison starts with what can be documented: facility status, medical scope, screening, emergency planning, medication disclosure, and continuity after departure.

Active view · clinical readiness

Start with the conditions around treatment.

A center should be able to describe the type of facility authorization it operates under and the scope of practice of the people providing on-site care. Titles alone are not enough; ask who is present, what they are authorized to do, and who makes clinical decisions.

Facility licensing typeAsk what authorization applies to the location and which services it covers.
On-site medical staffClarify qualifications, presence during care, responsibilities, and escalation authority.
Pre-admission screeningAsk what medical history, medication review, examination, and tests are required before acceptance.
Emergency equipmentAsk what equipment is immediately available and who is trained to use it.
Transfer arrangementsAsk how urgent transfer is handled, where it goes, and what happens while waiting.
RecordkeepingAsk what written information a client receives about screening, care, and follow-up.

Ibogaine has been associated with serious cardiac risk. The FDA’s discussion of drug-related heart-rhythm concerns is a useful reminder that medication and cardiac histories matter when evaluating screening claims.

Detail panel · admission review

Ask how screening changes the decision.

Pre-admission review should be more than a short questionnaire. Ask which tests are required, when results are reviewed, how current they must be, and what findings would lead a program to defer or decline admission. A medication review should also account for prescriptions, over-the-counter products, supplements, and recent substance use.

An electrocardiogram is commonly used to evaluate heart rhythm and electrical activity; the National Heart, Lung, and Blood Institute explains what an ECG records. A center does not become safe merely by mentioning an ECG. The useful question is how screening results are interpreted, documented, and connected to a plan for care or referral.

It can help to compare these answers against broader safety and risk considerations in Mexico, rather than treating a single positive answer as a complete assessment. Families can also use the questions in the Mexico ibogaine research guide to keep comparisons focused on verifiable details.

Documentary questions

Request specifics that can be compared.

Ask what form of ibogaine is used and whether the program discloses ibogaine hydrochloride (HCl) or total alkaloid (TA). Ask how medication is sourced, what documentation accompanies it, and how the program explains its handling. Disclosure makes comparison possible; it does not by itself establish quality or safety.

Questions about botanical origin are different from questions about product identity and medical oversight. Information about ibogaine plant seeds may describe the plant context, but a prospective client still needs clear answers about the specific medication and process offered by a program.

What facility authorization applies to this location?
Who is on site during care, and what is each person’s scope of practice?
What emergency equipment is available, and what transfer plan is in place?
Does the program disclose adverse events and its process for reviewing them?
What integration services are offered, and which aftercare referrals are available after departure?

Risk signals

Notice when key answers remain vague.

Red flags can include unwillingness to explain facility status, unclear staff roles, no meaningful discussion of screening or medication interactions, no concrete emergency plan, or pressure to decide before questions are answered. A program should not substitute confidence for documentation.

Be cautious with broad outcome claims. A reported ibogaine success rate can be hard to interpret without clear definitions, follow-up periods, missing-data handling, and adverse-event reporting. The clinical trial framework illustrates why methods and outcome definitions affect what a result can mean.

Likewise, personal accounts of an ibogaine trip experience may convey individual perspective, but they cannot answer questions about a particular facility’s emergency readiness or clinical procedures.

Summary view · continuity

A comparison should extend beyond the stay.

Ask what integration support exists after departure, whether it is delivered directly or through referral, and how a client can coordinate ongoing care locally. Aftercare plans should be specific about timing, access, and limits.

Questions about treatment context can be informed by broader material on ibogaine treatment for drug addiction, while people comparing options outside Mexico may find useful contrasts in Canadian ibogaine program context. Neither source replaces program-specific documentation.

“The point is not to find a perfect answer. It is to identify what is known, what is not documented, and what needs independent medical or legal advice.”

Questions in context

A few practical distinctions.

What documents should a prospective client ask to see?

Ask what facility authorization applies, who is responsible for clinical care, what pre-admission screening is required, what emergency equipment is on site, and what hospital transfer arrangement exists. Clear documentation supports comparison but is not a guarantee of outcome.

Does the source form of ibogaine matter?

Ask whether HCl or total alkaloid is used, how it is sourced, and what documentation accompanies it. A program should be able to answer plainly. The general ibogaine reference overview can help distinguish broad background from a center’s own product disclosure.

What should aftercare discussion include?

Ask what integration support is offered after departure, whether referrals are available, and how a client can coordinate follow-up with appropriate local health care. Promises of support should be concrete about availability and limits.

Why ask about adverse event reporting?

Transparency about adverse events is relevant because it shows whether a program can discuss complications, review processes, and changes to practice without minimizing uncertainty. A refusal to discuss this topic is information in itself.